GlaxoSmithKline PLC
08 December 2005
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
I give below details of changes in interests in the American Depositary Shares
(ADSs) of GlaxoSmithKline plc in respect of the under-mentioned Director:-
Dr T Yamada Exercise of options over 74,868 ADSs granted on 25 March 1996, which would
if not exercised have lapsed on 25 March 2006, under the SmithKline Beecham
US 1991 Share Option Plan at a price of $22.36494 per ADS, followed by the
sale of the resulting ADSs. These exercises and sales took place in two
tranches:
16,400 ADSs on 6 December 2005 at an average price of $50.52 per share. The
Company was advised of these transactions on 7 December 2005.
58,468 ADSs on 7 December 2005 at an average price of $50.1035 per share.
The Company was advised of these transactions on 8 December 2005.
Dr Yamada's total shareholding in the Company remains 72,805 ADSs.
Under the Company's share ownership requirements executive directors,
including Dr Yamada, are required to hold a shareholding in the Company to
the value of at least three times their annual base salary. Dr Yamada's
total shareholding is currently equivalent to more than four and a half
times his base salary.
This notification relates to a transaction notified in accordance with
Disclosure Rule 3.1.4R(1)(b).
S M Bicknell
Company Secretary
8 December 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.